A Study to Evaluate the Effect of Itraconazole and Rifampicin on the Pharmacokinetics of SY-5007 in Healthy Subjects - Trial NCT06332053
Access comprehensive clinical trial information for NCT06332053 through Pure Global AI's free database. This Phase 1 trial is sponsored by Shouyao Holdings (Beijing) Co. LTD and is currently Not yet recruiting. The study focuses on Healthy Subjects. Target enrollment is 28 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.
Study Focus
Sponsor & Location
Shouyao Holdings (Beijing) Co. LTD
Timeline & Enrollment
Phase 1
Apr 01, 2024
Jun 01, 2024
Primary Outcome
Cmax for SY-5007,Tmax for SY-5007,AUC0-t for SY-5007,AUC0-∞ for SY-5007,t½ for SY-5007,CL/F for SY-5007,Vz/F for SY-5007
Summary
This study is a single-center, open-lable and fixed sequence test conducted in healthy
 subjects to evaluate the pharmacokinetic effects of Itraconazole and Rifampicin on a single
 dose of SY-5007 Oral administration. It is planned to enroll 28 healthy subjects and assign
 them to two parallel test groups, Group A (SY-5007 combined with Itraconazole) and Group B
 (SY-5007 combined with Rifampicin).
ICD-10 Classifications
Data Source
ClinicalTrials.gov
NCT06332053
Non-Device Trial